Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners
News Nov 25, 2014
Allied-Bristol Life Sciences, LLC has announced that it has formed a strategic partnership with Synergy Partners R&D Solutions, LLC.
Synergy Partners, co-founded by Catherine D. Strader, Ph.D. and James S. MacDonald, Ph.D., comprises a network of over 20 well-respected experts that collectively have taken more than 100 drugs from discovery through development.
Their team of scientists offers expertise in areas such as disease biology, medicinal chemistry, process chemistry, toxicology, pharmacology and drug safety, and have proven track records at many of the world’s leading biopharmaceutical companies, including Bristol-Myers Squibb, Merck & Co., AstraZeneca, Pfizer Inc., Johnson & Johnson and Eli Lilly & Co.
This collective expertise offers essential insights for Allied-Bristol Life Sciences’ efforts to identify the most promising early-stage therapeutic opportunities at leading U.S. academic research institutions, and transform them into robust pre-clinical candidates for follow-on clinical development.
“The drug development team at Synergy Partners includes leaders within the biopharmaceutical industry in diseases of high interest to Allied-Bristol Life Sciences. We are pleased to have them joining our team as we move forward with this unique opportunity to advance academic innovations to drug candidates,” said Chris Silva, Chief Executive Officer of Allied Minds.
Allied-Bristol Life Sciences was formed earlier this year to identify discoveries from academic labs with promising therapeutic and commercial potential, and to drive these early-stage innovations from initial feasibility to pre-clinical candidacy. Synergy Partners will assist these efforts by lending strategic insights and decades of experience in the development, execution, and management of critical experiments and achievement of key milestones needed to successfully advance each research program.
“We are excited by the opportunity to work with Allied-Bristol Life Sciences to build a portfolio of novel and differentiated pre-clinical candidates,” said Synergy Partners’ Strader. “Synergy Partners is committed to bringing innovative new medicines to patients and Allied-Bristol Life Sciences offers a terrific model for optimizing innovation in the world of biopharmaceuticals.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE